|
1
|
Ito Y, Hirokawa M, Kihara M, et al:
Prognostic value of poorly differentiated carcinoma in Japanese
Society of Thyroid Surgery in a series of papillary thyroid
carcinoma patients: comparison with risk classification system in
Kuma Hospital. Endocr J. 59:817–821. 2012. View Article : Google Scholar
|
|
2
|
Xing M: Genetic alterations in the
phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.
Thyroid. 20:697–706. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stoscheck CM and King LE Jr: Role of
epidermal growth factor in carcinogenesis. Cancer Res.
46:1030–1037. 1986.PubMed/NCBI
|
|
4
|
Higashiyama S, Abraham JA, Miller J,
Fiddes JC and Klagsbrun M: A heparin-binding growth factor secreted
by macrophage-like cells that is related to EGF. Science.
251:936–939. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Raab G, Higashiyama S, Hetelekidis S, et
al: Biosynthesis and processing by phorbol ester of the cells
surface-associated precursor form of heparin-binding EGF-like
growth factor. Biochem Biophys Res Commun. 204:592–597. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Besner G, Higashiyama S and Klagsbrun M:
Isolation and characterization of a macrophage-derived
heparin-binding growth factor. Cell Regul. 1:811–819.
1990.PubMed/NCBI
|
|
7
|
Higashiyama S, Lau K, Besner GE, Abraham
JA and Klagsbrun M: Structure of heparin-binding EGF-like growth
factor. Multiple forms, primary structure, and glycosylation of the
mature protein. J Biol Chem. 267:6205–6212. 1992.PubMed/NCBI
|
|
8
|
Higashiyama S, Abraham JA and Klagsbrun M:
Heparin-binding EGF-like growth factor stimulation of smooth muscle
cell migration: dependence on interactions with cell surface
heparan sulfate. J Cell Biol. 122:933–940. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Marikovsky M, Breuing K, Liu PY, et al:
Appearance of heparin-binding EGF-like growth factor in wound fluid
as a response to injury. Proc Natl Acad Sci USA. 90:3889–3893.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hashimoto K, Higashiyama S, Asada H, et
al: Heparin-binding epidermal growth factor-like growth factor is
an autocrine growth factor for human keratinocytes. J Biol Chem.
269:20060–20066. 1994.PubMed/NCBI
|
|
11
|
Peoples GE, Blotnick S, Takahashi K,
Freeman MR, Klagsbrun M and Eberlein TJ: T lymphocytes that
infiltrate tumors and atherosclerotic plaques produce
heparin-binding epidermal growth factor-like growth factor and
basic fibroblast growth factor: a potential pathologic role. Proc
Natl Acad Sci USA. 92:6547–6551. 1995. View Article : Google Scholar
|
|
12
|
Miyagawa J, Higashiyama S, Kawata S, et
al: Localization of heparin-binding EGF-like growth factor in the
smooth muscle cells and macrophages of human atherosclerotic
plaques. J Clin Invest. 95:404–411. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Powell PP, Klagsbrun M, Abraham JA and
Jones RC: Eosinophils expressing heparin-binding EGF-like growth
factor mRNA localize around lung microvessels in pulmonary
hypertension. Am J Pathol. 143:784–793. 1993.PubMed/NCBI
|
|
14
|
Mangrulkar RS, Ono M, Ishikawa M,
Takashima S, Klagsbrun M and Nowak RA: Isolation and
characterization of heparin-binding growth factors in human
leiomyomas and normal myometrium. Biol Reprod. 53:636–646. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Higashiyama S, Iwamoto R, Goishi K, et al:
The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth
factor activity of the membrane-anchored heparin-binding EGF-like
growth factor. J Cell Biol. 128:929–938. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iwamoto R, Higashiyama S, Mitamura T,
Taniguchi N, Klagsbrun M and Mekada E: Heparin-binding EGF-like
growth factor, which acts as the diphtheria toxin receptor, forms a
complex with membrane protein DRAP27/CD9, which up-regulates
functional receptors and diphtheria toxin sensitivity. EMBO J.
13:2322–2330. 1994.
|
|
17
|
Yotsumoto F, Yagi H, Suzuki SO, et al:
Validation of HB-EGF and amphiregulin as targets for human cancer
therapy. Biochem Biophys Res Commun. 365:555–561. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miyamoto S, Hirata M, Yamazaki A, et al:
Heparin-binding EGF-like growth factor is a promising target for
ovarian cancer therapy. Cancer Res. 64:5720–5727. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Inui Y, Higashiyama S, Kawata S, et al:
Expression of heparin-binding epidermal growth factor in human
hepatocellular carcinoma. Gastroenterology. 107:1799–1804.
1994.PubMed/NCBI
|
|
20
|
Naef M, Yokoyama M, Friess H, Buchler MW
and Korc M: Co-expression of heparin-binding EGF-like growth factor
and related peptides in human gastric carcinoma. Int J Cancer.
66:315–321. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kobrin MS, Funatomi H, Friess H, Buchler
MW, Stathis P and Korc M: Induction and expression of
heparin-binding EGF-like growth factor in human pancreatic cancer.
Biochem Biophys Res Commun. 202:1705–1709. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ohnishi Y, Inoue H, Furukawa M, Kakudo K
and Nozaki M: Heparin-binding epidermal growth factor-like growth
factor is a potent regulator of invasion activity in oral squamous
cell carcinoma. Oncol Rep. 27:954–958. 2012.PubMed/NCBI
|
|
23
|
Haugen DR, Akslen LA, Varhaug JE and
Lillehaug JR: Expression of c-erbB-3 and c-erbB-4 proteins in
papillary thyroid carcinomas. Cancer Res. 56:1184–1188.
1996.PubMed/NCBI
|
|
24
|
Elenius K, Paul S, Allison G, Sun J and
Klagsbrun M: Activation of HER4 by heparin-binding EGF-like growth
factor stimulates chemotaxis but not proliferation. EMBO J.
16:1268–1278. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ito T, Seyama T, Mizuno T, et al: Unique
association of p53 mutations with undifferentiated but not with
differentiated carcinomas of the thyroid gland. Cancer Res.
52:1369–1371. 1992.PubMed/NCBI
|
|
26
|
Fogh J, Wright WC and Loveless JD: Absence
of HeLa cell contamination in 169 cell lines derived from human
tumors. J Natl Cancer Inst. 58:209–214. 1977.PubMed/NCBI
|
|
27
|
Sobin LH and Wittekind C: International
Union against Cancer. TNM Classification of Malignant Tumours. 6th
edition. Wiley-Liss; New York, NY: 2002
|
|
28
|
Ishiyama M, Miyazono Y, Sasamoto K, Ohkura
Y and Ueno K: A highly water-soluble disulfonated tetrazolium salt
as a chromogenic indicator for NADH as well as cell viability.
Talanta. 44:1299–1305. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Boyden S: The chemotactic effect of
mixtures of antibody and antigen on polymorphonuclear leucocytes. J
Exp Med. 115:453–466. 1962. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yoshida A, Anand-Apte B and Zetter BR:
Differential endothelial migration and proliferation to basic
fibroblast growth factor and vascular endothelial growth factor.
Growth Factors. 13:57–64. 1996. View Article : Google Scholar
|
|
31
|
Goodman SL, Vollmers HP and Birchmeier W:
Control of cell locomotion: perturbation with an antibody directed
against specific glycoproteins. Cell. 41:1029–1038. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Mannino RJ, Ballmer K, Zeltner D and
Burger MM: An inhibitor of animal cell growth increases
cell-to-cell adhesion. J Cell Biol. 91:855–859. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Giancotti FG and Ruoslahti E: Elevated
levels of the α5β1fibronectin receptor
suppress the transformed phenotype of Chinese hamster ovary cells.
Cell. 60:849–859. 1990.
|
|
34
|
Chomczynski P and Sacchi N: Single-step
method of RNA isolation by acid guanidinium
thiocyanate-phenol-chloroform extraction. Anal Biochem.
162:156–159. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Datta YH, Adams PT, Drobyski WR, Ethier
SP, Terry VH and Roth MS: Sensitive detection of occult breast
cancer by the reverse-transcriptase polymerase chain reaction. J
Clin Oncol. 12:475–482. 1994.
|
|
36
|
Noguchi S, Aihara T, Nakamori S, et al:
The detection of breast carcinoma micrometastases in axillary lymph
nodes by means of reverse transcriptase-polymerase chain reaction.
Cancer. 74:1595–1600. 1994. View Article : Google Scholar
|
|
37
|
Haugen DR, Akslen LA, Varhaug JE and
Lillehaug JR: Demonstration of a TGF-alpha-EGF-receptor autocrine
loop and c-myc protein over-expression in papillary thyroid
carcinomas. Int J Cancer. 55:37–43. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gorgoulis V, Aninos D, Priftis C, et al:
Expression of epidermal growth factor, transforming growth
factor-alpha and epidermal growth factor receptor in thyroid
tumors. In Vivo. 6:291–296. 1992.PubMed/NCBI
|
|
39
|
Aasland R, Akslen LA, Varhaug JE and
Lillehaug JR: Co-expression of the genes encoding transforming
growth factor-alpha and its receptor in papillary carcinomas of the
thyroid. Int J Cancer. 46:382–387. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Freeman MR, Paul S, Kaefer M, et al:
Heparin-binding EGF-like growth factor in the human prostate:
synthesis predominantly by interstitial and vascular smooth muscle
cells and action as a carcinoma cell mitogen. J Cell Biochem.
68:328–338. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Holting T, Siperstein AE, Clark OH and Duh
QY: Epidermal growth factor (EGF)- and transforming growth factor
alpha-stimulated invasion and growth of follicular thyroid cancer
cells can be blocked by antagonism to the EGF receptor and tyrosine
kinase in vitro. Eur J Endocrinol. 132:229–235. 1995. View Article : Google Scholar
|
|
42
|
Ongusaha PP, Kwak JC, Zwible AJ, et al:
HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer
Res. 64:5283–5290. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Miyoshi E, Higashiyama S, Nakagawa T,
Hayashi N and Taniguchi N: Membrane-anchored heparin-binding
epidermal growth factor-like growth factor acts as a tumor survival
factor in a hepatoma cell line. J Biol Chem. 272:14349–14355. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Shah JP, Loree TR, Dharker D, Strong EW,
Begg C and Vlamis V: Prognostic factors in differentiated carcinoma
of the thyroid gland. Am J Surg. 164:658–661. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Suzuki M, Raab G, Moses MA, Fernandez CA
and Klagsbrun M: Matrix metalloproteinase-3 releases active
heparin-binding EGF-like growth factor by cleavage at a specific
juxtamembrane site. J Biol Chem. 272:31730–31737. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Izumi Y, Hirata M, Hasuwa H, et al: A
metalloprotease-disintegrin, MDC9/meltrin-gamma/ADAM9 and PKCdelta
are involved in TPA-induced ectodomain shedding of
membrane-anchored heparin-binding EGF-like growth factor. EMBO J.
17:7260–7272. 1998. View Article : Google Scholar
|
|
47
|
Koshikawa N, Mizushima H, Minegishi T, et
al: Proteolytic activation of heparin-binding EGF-like growth
factor by membrane-type matrix metalloproteinase-1 in ovarian
carcinoma cells. Cancer Sci. 102:111–116. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Nakamura H, Ueno H, Yamashita K, et al:
Enhanced production and activation of progelatinase A mediated by
membrane-type 1 matrix metalloproteinase in human papillary thyroid
carcinomas. Cancer Res. 59:467–473. 1999.PubMed/NCBI
|
|
49
|
Aust G, Hofmann A, Laue S, Rost A, Kohler
T and Scherbaum WA: Human thyroid carcinoma cell lines and normal
thyrocytes: expression and regulation of matrix metalloproteinase-1
and tissue matrix metalloproteinase inhibitor-1 messenger-RNA and
protein. Thyroid. 7:713–724. 1997. View Article : Google Scholar
|
|
50
|
Hofmann A, Laue S, Rost AK, Scherbaum WA
and Aust G: mRNA levels of membrane-type 1 matrix metalloproteinase
(MT1-MMP), MMP-2, and MMP-9 and of their inhibitors TIMP-2 and
TIMP-3 in normal thyrocytes and thyroid carcinoma cell lines.
Thyroid. 8:203–214. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Higashiyama S, Iwabuki H, Morimoto C,
Hieda M, Inoue H and Matsushita N: Membrane-anchored growth
factors, the epidermal growth factor family: beyond receptor
ligands. Cancer Sci. 99:214–220. 2008. View Article : Google Scholar : PubMed/NCBI
|
